These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8429118)

  • 21. Propranolol does not further decrease the clearance of antipyrine in patients with alcoholic cirrhosis.
    Larrey D; Lebrec D; Bercoff E; Pessayre D
    Clin Sci (Lond); 1983 Aug; 65(2):203-5. PubMed ID: 6602683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon.
    Kitteringham NR; Büstgens L; Brundert E; Mineshita S; Ohnhaus EE
    Eur J Clin Pharmacol; 1984; 26(1):65-70. PubMed ID: 6714293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum bilirubin: a prognostic factor in primary biliary cirrhosis.
    Shapiro JM; Smith H; Schaffner F
    Gut; 1979 Feb; 20(2):137-40. PubMed ID: 428825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of antipyrine clearance to measure liver damage in psoriatic patients receiving methotrexate.
    Paramsothy J; Strange R; Sharif H; Collins M; Shaw P; Lawrence CM
    Br J Dermatol; 1988 Dec; 119(6):761-5. PubMed ID: 3203069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of flecainide in patients with cirrhosis of the liver.
    McQuinn RL; Pentikäinen PJ; Chang SF; Conard GJ
    Clin Pharmacol Ther; 1988 Nov; 44(5):566-72. PubMed ID: 3141098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ibuprofen does not impair antipyrine clearance.
    Abernethy DR; Greenblatt DJ
    J Clin Pharmacol; 1983; 23(11-12):517-22. PubMed ID: 6662976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical value of serum bilirubin subfractionation by high-performance liquid chromatography and conventional methods in patients with primary biliary cirrhosis.
    Jansen PL; Peters WH; Janssens AR
    J Hepatol; 1986; 2(3):485-94. PubMed ID: 3722796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipyrine elimination test as a guideline for selecting patients for transhepatic biliary drainage.
    Ramesh VS; Kochhar R; Garg SK; Wig JD; Gupta NM
    J Gastroenterol Hepatol; 1990; 5(3):219-22. PubMed ID: 2103402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients.
    Grieco A; Castellano R; Matera A; Marcoccia S; Di Rocco P; Ragazzoni E; Vecchio FM; Gasbarrini G
    J Gastroenterol Hepatol; 1998 May; 13(5):460-6. PubMed ID: 9641640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison between antipyrine and aminopyrine blood clearances.
    Kawasaki S; Imamura H; Kokudo N; Bandai Y; Sanjo K; Idezuki Y
    Hepatogastroenterology; 1992 Aug; 39(4):344-6. PubMed ID: 1427580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study.
    Balasubramaniam K; Grambsch PM; Wiesner RH; Lindor KD; Dickson ER
    Gastroenterology; 1990 Jun; 98(6):1567-71. PubMed ID: 2338193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition of antipyrine and phenytoin correlated with age and liver volume in man.
    Bach B; Hansen JM; Kampmann JP; Rasmussen SN; Skovsted L
    Clin Pharmacokinet; 1981; 6(5):389-96. PubMed ID: 7333060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of antipyrine in epileptic patients.
    Rimmer EM; Routledge PA; Tsanaclis LM; Richens A
    Br J Clin Pharmacol; 1986 May; 21(5):511-4. PubMed ID: 3718808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased mean platelet volume is related to histologic severity of primary biliary cirrhosis.
    Tahtaci M; Yurekli OT; Bolat AD; Balci S; Akin FE; Buyukasik NS; Ersoy O
    Eur J Gastroenterol Hepatol; 2015 Dec; 27(12):1382-5. PubMed ID: 26308712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis.
    Minuk GY; Bohme CE; Burgess E; Hershfield NB; Kelly JK; Shaffer EA; Sutherland LR; Van Rosendaal G
    Gastroenterology; 1988 Nov; 95(5):1356-63. PubMed ID: 3169499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced hepatic drug clearance in patients with cystic fibrosis.
    Kearns GL; Mallory GB; Crom WR; Evans WE
    J Pediatr; 1990 Dec; 117(6):972-9. PubMed ID: 2246703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man.
    Daneshmend TK; Warnock DW; Ene MD; Johnson EM; Parker G; Richardson MD; Roberts CJ
    J Antimicrob Chemother; 1983 Aug; 12(2):185-8. PubMed ID: 6311786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipyrine metabolism in patients with liver metastases from colorectal cancer.
    Grieco A; Barone C; Coletta P; Castellano R; Ragazzoni E; Cassano A; Astone A; Gambassi G
    Cancer; 1992 Sep; 70(6):1477-82. PubMed ID: 1515999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipyrine kinetics in undernourished diabetics.
    Shobha JC; Raghuram TC; Kumar AD; Krishnaswamy K
    Eur J Clin Pharmacol; 1991; 41(4):359-61. PubMed ID: 1804653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of chlorambucil for primary biliary cirrhosis.
    Hoofnagle JH; Davis GL; Schafer DF; Peters M; Avigan MI; Pappas SC; Hanson RG; Minuk GY; Dusheiko GM; Campbell G
    Gastroenterology; 1986 Dec; 91(6):1327-34. PubMed ID: 3533699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.